Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

129.76USD
2:29am IST
Change (% chg)

$-0.49 (-0.38%)
Prev Close
$130.25
Open
$130.20
Day's High
$132.88
Day's Low
$125.41
Volume
46,306
Avg. Vol
51,744
52-wk High
$145.59
52-wk Low
$68.47

Summary

Name Age Since Current Position

Michael Jensen

47 2013 Chairman of the Board, Senior Vice President, Chief Legal Officer

Jan Moeller Mikkelsen

59 2007 President, Chief Executive Officer, Board Member, Executive Director

Scott Smith

45 2016 Chief Financial Officer, Senior Vice President

Lotte Soenderbjerg

57 2007 Senior Vice President, Chief Administrative Officer

Flemming Jensen

58 2015 Senior Vice President - Product Supply

Thomas Larson

57 2018 Senior Vice President, Chief Commercial Officer

Jonathan Leff

61 2016 Senior Vice President, Chief Medical Officer

Jens Okkels

58 2019 Senior Vice President - Product Development

Juha Punnonen

2018 Senior Vice President - Head of Oncology

Kennett Sprogoee

40 2016 Senior Vice President - Product Innovation and Research

Peter Rasmussen

50 2016 Principal Accounting Officer, Vice President - Finance

Lisa Bright

51 2017 Independent Director

Albert Cha

46 2014 Independent Director

James Healy

53 2014 Independent Director

Lars Holtug

60 2018 Independent Director

Birgitte Volck

56 2016 Independent Director

Biographies

Name Description

Michael Jensen

Mr. Michael Wolff Jensen, L.L.M., is the Chairman of the Board, Senior Vice President, Chief Legal Officer of Ascendis Pharma A/S since January 2008 and as Senior Vice President, General Counsel since June 2013. In addition, Mr. Jensen served as Acting Chief Financial Officer from May 2008 to June 2013. From October 2010 to June 2013, Mr. Jensen served as Senior Legal Advisor and Head of Partnerships (France) for the renewable business division of Dong Energy A/S, the Danish State-owned utility company. Prior to Ascendis Pharma, Mr. Jensen served as Executive Vice President & Chief Financial Officer of Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company, from 2003 to 2008. Prior to joining Veloxis, Mr. Jensen served as Senior Vice President & Chief Financial Officer of Genmab A/S, a publicly traded biotechnology company from 2000 to 2003. Mr. Jensen also currently serves as Chairman of the board of directors of two biotechnology companies; one publicly traded, Eurocine Vaccines AB, and one privately held. Mr. Jensen received an L.L.M. degree from the University of Copenhagen.

Jan Moeller Mikkelsen

Mr. Jan Moeller Mikkelsen is the President, Chief Executive Officer, Board Member, Executive Director of Ascendis Pharma A/S. He co-founded Ascendis Pharma and has served as our President and Chief Executive Officer and as a member of our board of directors since December 2007. From 2002 to 2006, Mr. Mikkelsen served as President and Chief Executive Officer of LifeCycle Pharma A/S, now known as Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company. From 2000 to 2002, Mr. Mikkelsen served as Co-President and subsequently as President of the Pharmaceutical Division of Maxygen, Inc., a protein pharmaceuticals business. Mr. Mikkelsen co-founded ProFound Pharma A/S, a biopharmaceutical company that was later acquired by Maxygen, Inc., and he served as Co-Chief Executive Officer from 1999 to 2000. Prior to founding ProFound, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, and served as its Vice President of protein discovery from 1991 to 1999. Mr. Mikkelsen currently serves as a member of the advisory board of Inspirion Delivery Technologies, a specialty pharmaceutical company. Mr. Mikkelsen is Cand. Scient. in Biochemistry from the University of Odense.

Scott Smith

Mr. Scott T. Smith is the Chief Financial Officer, Senior Vice President of Ascendis Pharma A/S since August 8, 2016. He most recently served as Director of the Healthcare Investment Banking Group at Wedbush Securities, from 2012 to 2016, where he led the healthcare team and oversaw a substantial increase in revenue and transaction volume. From 2009 to 2012, Mr. Smith served as a Managing Director at Wedbush. Prior to joining Wedbush, Mr. Smith served as a Director in the Global Healthcare Investment Banking Group at Merrill Lynch where he began his career in 1995. He has also worked in sales, marketing and strategy roles for various companies, including start-ups and a Fortune Global 500 company. Mr. Smith received his MBA from the Stanford University Graduate School of Business and graduated magna cum laude with a BA in Economics/Accounting - Physics from Claremont McKenna College.

Lotte Soenderbjerg

Ms. Lotte Soenderbjerg is the Senior Vice President, Chief Administrative Officer at Ascendis Pharma A/S since December 2007. She has been Managing Director of Ascendis Pharma GmbH at the Company. Prior to joining Ascendis Pharma, Ms. Soenderbjerg served as Senior Director of Human Resources and as Finance Director at Veloxis Pharmaceuticals A/S from 2003 to 2007. Prior to joining Veloxis Pharmaceuticals A/S, Ms. Soenderbjerg served as Senior Director of Finance and Human Resources at Acadia Pharmaceuticals Inc., a publicly traded biotechnology company from 1996 to 2003. Prior to her career in biotech, Ms. Soenderbjerg was the Executive Secretary for the CEO and Board of Directors of Novo Nordisk A/S. Ms. Soenderbjerg received a Masters of Arts in International Business Communications from University of Aarhus.

Flemming Jensen

Mr. Flemming Steen Jensen L.L.M., is the Senior Vice President - Product Supply of Ascendis Pharma A/S since August 2015. Prior to this, Mr. Jensen served as Corporate Vice President for Global Pharma Consulting and Business Development and member of the management team at NNE Pharmaplan A/S, an engineering and consulting company (part of Novo Nordisk A/S), from October 2014 to July 2015. From 1999 to September 2014, Mr. Jensen served as Executive Vice President of Product Supply (Production, Supply Chain, Engineering and Maintenance, Business Improvements, Quality Assurance and Health, Safety and Environment) and member of the Board of Management of ALK-Abello A/S, a pharmaceutical company. From 1986 to 1999, Mr. Jensen held several management positions relating to Development, Manufacturing and Engineering within Novo Nordisk A/S, a pharmaceutical company. Mr. Jensen is also a member of various boards of directors and advisory boards of privately held companies in the life sciences industry. Mr. Jensen holds a M.Sc. in Pharmacy from the University of Copenhagen.

Thomas Larson

Mr. Thomas A. Larson is the Senior Vice President, Chief Commercial Officer of the Company. Mr. Larson was Vice President and Chief Commercial Officer at Mitsubishi Tanabe Pharma America, a pharmaceutical company, since 2016. At Mitsubishi, he established the U.S. commercial organization and successfully launched the company’s first U.S. pharmaceutical product, Radicava9, the first amyotrophic lateral sclerosis (ALS) therapy approved in the U.S. in over 20 years. From 2013 to 2016, Mr. Larson was a member of the commercial team for Marathon Pharmaceuticals, a biopharmaceuticals company, where he helped build the commercial infrastructure. Prior to Marathon, he worked for Boehringer-lngelheim, a pharmaceutical company, and Johnson & Johnson, a broad based healthcare Company, where he oversaw sales activities focused on hospital and specialty markets. Mr. Larson began his career at Abbott Laboratories, a healthcare company, in 1985, where he worked in research and development, sales, market access and marketing roles of increasing responsibility over his 18-year tenure, including leadership positions in the commercial organization supporting orphan drug, hospital, biologics and specialty product launches. Mr. Larson holds a Bachelor of Science in Biochemistry from Northern Michigan University.

Jonathan Leff

Dr. Jonathan A. Leff, M.D., is the Senior Vice President, Chief Medical Officer of Ascendis Pharma A/S since February 25, 2016. From March 2015 until joining Ascendis Pharma, Dr. Leff consulted with various clients in the field of clinical development. Prior to joining Ascendis Pharma, Dr. Leff served as the Executive Vice President, Research and Development for InterMune, Inc., a biotechnology company, from February 2012 to March 2015. Prior to InterMune, Dr. Leff served as Chief Medical Officer from February 2011 to February 2012 at KaloBios Pharmaceuticals, Inc., a biotechnology company, and previously served as Vice President and Chief Medical Officer at Halozyme Therapeutics, Inc. from 2009 to 2010. Prior to joining Halozyme from 2007 to 2009, Dr. Leff was Vice President and Global Head of Inflammation Clinical Development at Roche. From 2002 to 2007, Dr. Leff held various positions at Amgen Inc., including Vice President, North American Medical Affairs. Dr. Leff received a B.A. in Chemistry from the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.

Jens Okkels

Dr. Jens Sigurd Okkels, Ph.D., M.Sc., is the Senior Vice President - Product Development of the Company. Prior to joining Ascendis, Dr. Okkels worked as an independent consultant at Okkels Consulting, GmbH from January 2018 to March 2019. From October 2011 to December 2017, Dr. Okkels served as Vice President, CMC Center Europe at Takeda Pharmaceutical Company Ltd., a pharmaceutical company. Prior to that, Dr. Okkels held various positions at Nycomed (acquired by Takeda Pharmaceutical) between 2005 and 2011. From 1999 to 2005, he worked as Director of Molecular Biology and Fermentation and Director of Science and Technology for Profound Pharma A/S (acquired by Maxygen Inc., a biopharmaceutical company, in 2000). From 1992 to 1999, Dr. Okkels worked in various positions at Novo Nordisk A/S, a pharmaceutical company. Dr. Okkels received his Ph.D. in Molecular Biology and Biochemistry from The Royal Veterinary and Agricultural University in Denmark and holds an M.Sc. in Biochemistry from University of Copenhagen in Denmark.

Juha Punnonen

Dr. Juha Punnonen, M.D. Ph.D., is the Senior Vice President - Head of Oncology of the Company. Dr. Punnonen served as Executive Director, Oncology Discovery Research, at Merck & Co., Inc., a pharmaceutical company, where he coordinated preclinical research and early development programs for Merck Oncology, including external clinical collaborations for Merck’s anti-PD-1 antibody, Keytruda® (pembrolizumab). Prior to his tenure at Merck, he served as CEO and Head of Research and Development at STATegics, Inc., a biotechnology company he co-founded in 2007. Prior to STATegics, Dr. Punnonen was Vice President and Head of Biology and Pharmacology at Maxygen, Inc., a company developing next-generation protein therapeutics and vaccines. He began his industry career in 1994 as a scientist with DNAX Research Institute (later Schering-Plough Biopharma and Merck Research Labs), where he had done his postdoctoral training in cytokine research. His clinical experience is in internal medicine, pediatrics and medical microbiology. Dr. Punnonen received his M.D. and Ph.D. (immunology) from the University of Turku, Finland.

Kennett Sprogoee

Dr. Kennett Sprogoee, Ph.D., is the Senior Vice President - Product Innovation and Research of Ascendis Pharma A/S since January 2016. He has held positions of increasing responsibility at Ascendis Pharma since December 2007 and as Vice President, Product Innovation from June 2014 to January 2016 and Director, Portfolio Development from November 2012 to June 2014. Prior to joining Ascendis Pharma, Dr. Sprogoee conducted research at the University of Copenhagen, where he applied novel hyphenated screening technologies to expedite discovery of drug leads from natural sources. Dr. Sprogoee holds a Ph.D. in Natural Products Chemistry from the University of Copenhagen and a M.Sc. in Pharmacy from the Danish University of Pharmaceutical Sciences.

Peter Rasmussen

Mr. Peter Rasmussen is the Principal Accounting Officer, Vice President - Finance of Ascendis Pharma A/S since February 2016. He has been Principal Accounting Officer, Vice President - Finance at the Company since March 2014. Prior to joining Ascendis Pharma, Mr. Rasmussen worked as a financial consultant for Ascendis Pharma from October 2013 to March 2014. From June 2008 to August 2012, Mr. Rasmussen served as the Chief Financial Officer of AdvanDx, Inc., a privately held medical device company. From 2007 to 2008, prior to AdvanDx, Mr. Rasmussen served as Head of Finance at Veloxis Pharmaceuticals A/S. Mr. Rasmussen is a state-authorized public accountant in Denmark and received an M.Sc. in Business Economics and Auditing from Copenhagen Business School.

Lisa Bright

Ms. Lisa Bright is the Independent Director of the Company. Ms. Bright has served as President International for Intercept Pharmaceuticals Europe Limited, a biopharmaceutical company. Prior to her appointment as President International, Ms. Bright held various senior leadership positions from November 2014 to July 2016 at Intercept Pharmaceuticals including Chief Commercial and Corporate Affairs Officer and Senior Vice President, Head of EUCA. During her tenure at Intercept, Ms. Bright has overseen the development of the global launch of an orphan medicine in the United States and Europe, including building the commercial organization in the United States and establishing legal affiliates and teams across Europe and Canada. Ms. Bright currently serves as a member of the board of directors of Dechra Pharmaceuticals PLC, a veterinary pharmaceutical company. From 2008 to November 2014, Ms. Bright held various leadership positions at Gilead Sciences Ltd., a biopharmaceutical company, including Vice President, Head of Government Affairs, Europe, Asia, Middle East and Australasia, Vice President and Head of HCV Launch Planning, Vice President and Head of Northern Europe and General Manager, UK and Ireland. Prior to Gilead Sciences, Ms. Bright served in various positions of increasing responsibility at GlaxoSmithKline plc from 1997 to 2006 including Vice President Commercial Planning and Operations and Vice President General Manager NZ and Vice President Head of Sales, UK and Ireland. Prior to that, Ms. Bright also worked at Sanofi from 1992 to 1996 and GlaxoSmithKline from 1989 to 1992. Ms. Bright received her B.Sc. in Pharmacology from University College London, United Kingdom.

Albert Cha

Dr. Albert Cha, M.D. Ph.D., is an Independent Director of Ascendis Pharma A/S since November 2014. In 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions, most recently as a managing partner. Dr. Cha currently serves as a member of the board of directors of several privately held biotechnology and medical device companies. Dr. Cha serves as a member of the board of directors at the following publicly traded companies: AirXpanders Inc., Aclaris Therapeutics, Inc., Carbylan Therapeutics, Inc., and ProNAi Therapeutics, Inc. From June 2002 through February 2009, Dr. Cha served as a member of the board of directors at BioForm Medical, Inc., a publicly traded medical aesthetics company. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.

James Healy

Dr. James I. Healy, M.D. Ph.D., is an Independent Director of Ascendis Pharma A/S since November 2014. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Amarin Corporation plc, Auris Medical Holding AG, Hyperion Therapeutics, Inc., Coherus BioSciences, Inc. and several private companies. Previously, he served as a board member of InterMune, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV, KaloBios Pharmaceuticals, Inc. and several private companies. Dr. Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley.

Lars Holtug

Mr. Lars Holtug, M.Sc., CPA is an Independent Director of the Company. Mr. Holtug was a partner at PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (“PWC”) from 1993 to 2015. Mr. Holtug also currently serves as chairman of Gaming Investment A/S, a gaming solutions provider, and its 10 subsidiaries, and of Valizo ApS, a luggage transportation service. Furthermore, Mr. Holtug serves as a board member and Audit Committee Chairman of Adform A/S, an ad serving provider. Previously, he was Chairman of PWC in Denmark from 2005 to 2009. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriserede Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr. Holtug holds an M.Sc. from Copenhagen Business School and is educated as a state authorized public accountant in Denmark.s

Birgitte Volck

Dr. Birgitte Volck, M.D. Ph.D., is an Independent Director of the Company. Dr. Volck has served as the President R&D at AVROBIO Inc., a phase 2 clinical stage gene therapy company. From June 2016 to August 2018, Dr. Volck served as head of Research and Development, Rare Diseases for GlaxoSmithKline plc. From August 2012 to 2016, Dr. Volck served as the Chief Medical Officer and Senior Vice President of Development at Swedish Orphan Biovitrum AB, a biopharmaceutical company. From 2007 to July 2012, Dr. Volck held various positions at Amgen Inc., a biopharmaceutical company, including Executive Development Director, Bone, Neuroscience & Inflammation. Prior to Amgen, from 2004 to 2007, Dr. Volck served as Nordic Medical Director and Project Director at Genzyme A/S, a biotechnology company. From 2001 to 2004, Dr. Volck served as Head of Clinical Development and Medical Affairs at Pharmexa, a biotechnology company. From May 2017 to May 2018, Dr. Volck served as a director for Wilson Therapeutics AB, a biotechnology company. Since May 2016, Dr. Volck has served as a director for TFS International, a clinical research organization. Dr. Volck received her M.D. and Ph.D. degrees from Copenhagen University, Denmark.